Omnicom, Validic team up to help pharma marketers tap wearables data

Apple Watch

Everyone in healthcare is trying to figure out wearables, including pharma. Omnicom Health Group is counting on a new partnership with digital health platform Validic to go a long way in helping its drugmaker clients do that.

Of course, the plan extends beyond data from “wearables.” A wide range of personal health monitoring gadgets--including ingestibles, embeddables, sensors, robotics and home health devices--now collect patient data.

“Validic gives us the way to manage any type of device for any disease state in a HIPAA-compliant way and deliver a more comprehensive communications plan,” Jo Ann Saitta, chief digital health office at OmnicomHealthGroup, told FiercePharma.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

She added, “The monitoring of biometric data now feeds the creative and the way in which we have to engage patients and doctors. … It can be very overwhelming. There are tons of wearables, lots of data, and people are asking ‘what do I do with it’ and ‘what if my doctor doesn’t understand it.’ All these things now factor into how we communicate with patients and doctors.”

Along with Validic and other Omnicom partners including IBM Watson, Google and Twitter Health, the agency is coming off the MedTech Expo it sponsored as part of the Cannes Lions Health festival. The topics and discussions presented along with personal monitoring devices included cognitive computing and big data, telemedicine, personalized medicine, virtual and augmented reality and 3-D printing.

“Technology and data are not only changing the delivery of healthcare communications but also changing the delivery of medicine,” Saitta said. “…This is uncharted territory for pharma definitely, but it’s also uncharted territory for a lot of partners in healthcare.”

- see the news release

Related Articles:
Omnicom's healthcare push continues with Rabin Martin buyout
Two agency giants duke it out for GlaxoSmithKline $900M media account
Can pharma + tech wearables be a match made in patient heaven?
Wearable healthcare market to jump to $41B in 2020: Reuters

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Roche’s targeted cancer drug Rozlytrek is officially cleared for a U.S. launch—and in not one, but two indications.

Amarin may still be waiting for the FDA to include new risk-reduction info to Vascepa's label, but in the meantime, it's getting prepared.